ADC Therapeutics (ADCT)
Develops and sells ZYNLONTA while pursuing broader lymphoma use.
$1.32
Pre-market−0.01 (−0.38%)
At close$1.33(+7.29%)
Something off on this page? Send us feedback.
Next report
Nov 10, 2026
in 68 days
EPS estimate
−$0.21
Revenue estimate
$18.9M
Fiscal quarter
Q3 FY26
EPSReportedEstimate
Mar '25May '25Aug '25Nov '25Mar '26May '26Aug '26Nov '26
Reported−$0.29−$0.36−$0.50−$0.30−$0.04−$0.21−$0.11Pending
Estimate−$0.35−$0.38−$0.36−$0.40−$0.32−$0.19−$0.22−$0.21
Surprise+17.1%+5.3%−38.9%+25.0%+87.5%−10.5%+49.1%—
RevenueReportedEstimate
Mar '25May '25Aug '25Nov '25Mar '26May '26Aug '26Nov '26
Reported$16.9M$23.0M$18.8M$16.4M$23.1M$20.9M$19.2MPending
Estimate$19.0M$17.5M$18.2M$21.6M$22.3M$20.0M$18.9M$18.9M
Surprise−11.0%+31.3%+3.5%−23.8%+3.4%+4.3%+1.9%—
History
| Date | Estimate | Reported | Surprise |
|---|---|---|---|
| Nov 2026 | −$0.21 | — | — |
| Aug 2026 | −$0.22 | −$0.11 | +49.1% |
| May 2026 | −$0.19 | −$0.21 | −10.5% |
| Mar 2026 | −$0.32 | −$0.04 | +87.5% |
| Nov 2025 | −$0.40 | −$0.30 | +25.0% |
The latest year is open to everyone — the 30 quarters behind it read with an account. Sign in | |||
| Aug 2025 | |||
| May 2025 | |||
| Mar 2025 | |||
| Nov 2024 | |||
| Aug 2024 | |||
| May 2024 | |||
| Mar 2024 | |||
| Nov 2023 | |||
| Aug 2023 | |||
| May 2023 | |||
| Feb 2023 | |||
| Nov 2022 | |||
| Aug 2022 | |||
| May 2022 | |||
| Mar 2022 | |||
| Nov 2021 | |||
| Aug 2021 | |||
| May 2021 | |||
| Mar 2021 | |||
| Nov 2020 | |||
| Aug 2020 | |||
| Mar 2020 | |||
| Dec 2019 | |||
| Sep 2019 | |||
| Jun 2019 | |||
| Mar 2019 | |||
| Dec 2018 | |||
| Sep 2018 | |||
| Jun 2018 | |||
| Mar 2018 | |||
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Reaction |
|---|---|---|---|---|---|---|---|
| Nov 10, 2026 | −$0.21 | — | — | $18.9M | — | — | — |
| Aug 13, 2026 | −$0.22 | −$0.11 | +49.1% | $18.9M | $19.2M | +1.9% | −14.6% |
| May 4, 2026 | −$0.19 | −$0.21 | −10.5% | $20.0M | $20.9M | +4.3% | +2.2% |
| Mar 10, 2026 | −$0.32 | −$0.04 | +87.5% | $22.3M | $23.1M | +3.4% | +1.7% |
| Nov 10, 2025 | −$0.40 | −$0.30 | +25.0% | $21.6M | $16.4M | −23.8% | −5.7% |
The latest year is open to everyone — the 30 quarters behind it read with an account. Sign in | |||||||
| Aug 12, 2025 | |||||||
| May 14, 2025 | |||||||
| Mar 27, 2025 | |||||||
| Nov 7, 2024 | |||||||
| Aug 6, 2024 | |||||||
| May 6, 2024 | |||||||
| Mar 13, 2024 | |||||||
| Nov 7, 2023 | |||||||
| Aug 8, 2023 | |||||||
| May 9, 2023 | |||||||
| Feb 28, 2023 | |||||||
| Nov 8, 2022 | |||||||
| Aug 9, 2022 | |||||||
| May 9, 2022 | |||||||
| Mar 3, 2022 | |||||||
| Nov 2, 2021 | |||||||
| Aug 3, 2021 | |||||||
| May 6, 2021 | |||||||
| Mar 18, 2021 | |||||||
| Nov 12, 2020 | |||||||
| Aug 18, 2020 | |||||||
| Mar 2, 2020 | |||||||
| Dec 31, 2019 | |||||||
| Sep 30, 2019 | |||||||
| Jun 30, 2019 | |||||||
| Mar 31, 2019 | |||||||
| Dec 31, 2018 | |||||||
| Sep 30, 2018 | |||||||
| Jun 30, 2018 | |||||||
| Mar 31, 2018 | |||||||